Clinical Trial Update: A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of varlilumab (anti-CD27), ipilimumab, and CDX-1401 in patients with unresectable stage III or stage IV melanoma ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CDX-1401
• Varlilumab (varlilumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Celldex Therapeutics | Conditions: Unresectable Stage III or Stage IV Melanoma | Phase 1, Phase 2 | Status: TERMINATED